Trial Profile

Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Atients With Myelodysplastic Syndromes (MDS) After Failure of Hypomethylating Agent-Based Therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tosedostat (Primary)
Indications Myelodysplastic syndromes
Focus Therapeutic Use
Acronyms IST-CTI-MDS

Most Recent Events

13 Mar 2018 Status changed from recruiting to completed.
12 Dec 2017 Results (n=12) assessing efficacy, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
01 Mar 2017 Planned End Date changed from 1 Sep 2018 to 1 Mar 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com